Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Van ECK Associates Corp

Van ECK Associates Corp raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 18.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,818 shares of the biopharmaceutical company's stock after acquiring an additional 10,419 shares during the quarter. Van ECK Associates Corp owned about 0.05% of Alnylam Pharmaceuticals worth $15,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Huntington National Bank raised its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $33,000. Washington Trust Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $42,000. Finally, True Wealth Design LLC increased its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 153 shares during the period. Institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ALNY. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, February 14th. Scotiabank decreased their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a report on Friday, February 14th. HC Wainwright reaffirmed a "buy" rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Wolfe Research cut shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Finally, StockNews.com lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $299.48.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the company's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares in the company, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,356 shares of company stock worth $22,498,551 over the last ninety days. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.2 %

Alnylam Pharmaceuticals stock traded up $0.51 during midday trading on Wednesday, hitting $250.51. 740,941 shares of the stock were exchanged, compared to its average volume of 693,172. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock's 50-day simple moving average is $253.96 and its 200 day simple moving average is $263.29. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market capitalization of $32.43 billion, a price-to-earnings ratio of -115.44 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.